The aim of this open-label pilot study was to assess the efficacy and safety of the novel anticonvulsant agent, levetiracetam, for the treatment of alcohol dependence. A maximal dose of 2000 mg was administered daily for 10 weeks to alcohol dependent subjects (n = 20). Mean reported ethanol intake declined significantly from 5.3 to 1.7 standard drinks per day. Levetiracetam was well tolerated by most subjects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377927 | PMC |
| http://dx.doi.org/10.1080/00952990802082180 | DOI Listing |
Publication Analysis
Top Keywords
effects levetiracetam
4
levetiracetam alcohol
4
alcohol consumption
4
consumption alcohol-dependent
4
alcohol-dependent subjects
4
subjects open
4
open label
4
label study
4
study aim
4
aim open-label
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!